PURPOSE: To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR). PATIENTS AND METHODS: This retrospective analysis included 1,731 patients with stage I to III noninflammatory breast cancer treated between 1988 and 2005 with primary chemotherapy (PC). Ninety-one percent of patients received anthracycline-based PC, and 66% received additional taxane therapy. pCR was defined as no evidence of invasive tumor in the breast and axillary lymph nodes. RESULTS: Median age was 49 years (range, 19 to 83 years). Sixty-seven percent of patients (n = 1,163) had HR-positive tumors. A pCR was observed in 225 (13%) of 1,731 patients; pCR rates were 24% in HR-negative tumors and 8% in HR-positive tumors (P < .001). A significant survival benefit for patients who achieved pCR compared with no pCR was observed regardless of HR status. In the HR-positive group, 5-year overall survival (OS) rates were 96.4% v 84.5% (P = .04) and 5-year progression-free survival (PFS) rates were 91.1% v 65.3% (P < .0001) for patients with and without pCR, respectively. For the HR-negative group, 5-year OS rates were 83.9% v 67.4% (P = .003) and 5-year PFS rates were 83.4% v 50.0% (P < .0001) for patients with and without pCR, respectively. After adjustment for adjuvant hormonal treatment, HR status, clinical stage, and nuclear grade, patients who achieved a pCR had 0.36 times the risk of death. CONCLUSION: pCR is associated with better outcome regardless of HR status in breast cancer patients who receive PC.
PURPOSE: To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR). PATIENTS AND METHODS: This retrospective analysis included 1,731 patients with stage I to III noninflammatory breast cancer treated between 1988 and 2005 with primary chemotherapy (PC). Ninety-one percent of patients received anthracycline-based PC, and 66% received additional taxane therapy. pCR was defined as no evidence of invasive tumor in the breast and axillary lymph nodes. RESULTS: Median age was 49 years (range, 19 to 83 years). Sixty-seven percent of patients (n = 1,163) had HR-positive tumors. A pCR was observed in 225 (13%) of 1,731 patients; pCR rates were 24% in HR-negative tumors and 8% in HR-positive tumors (P < .001). A significant survival benefit for patients who achieved pCR compared with no pCR was observed regardless of HR status. In the HR-positive group, 5-year overall survival (OS) rates were 96.4% v 84.5% (P = .04) and 5-year progression-free survival (PFS) rates were 91.1% v 65.3% (P < .0001) for patients with and without pCR, respectively. For the HR-negative group, 5-year OS rates were 83.9% v 67.4% (P = .003) and 5-year PFS rates were 83.4% v 50.0% (P < .0001) for patients with and without pCR, respectively. After adjustment for adjuvant hormonal treatment, HR status, clinical stage, and nuclear grade, patients who achieved a pCR had 0.36 times the risk of death. CONCLUSION: pCR is associated with better outcome regardless of HR status in breast cancerpatients who receive PC.
Authors: Marco Colleoni; Bernard F Cole; Giuseppe Viale; Meredith M Regan; Karen N Price; Eugenio Maiorano; Mauro G Mastropasqua; Diana Crivellari; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Barry A Gusterson Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544
Authors: Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Shigeto Ueda; Darren Roblyer; Albert Cerussi; Amanda Durkin; Anais Leproux; Ylenia Santoro; Shanshan Xu; Thomas D O'Sullivan; David Hsiang; Rita Mehta; John Butler; Bruce J Tromberg Journal: Cancer Res Date: 2012-07-09 Impact factor: 12.701
Authors: Claudia Palena; Mario Roselli; Mary T Litzinger; Patrizia Ferroni; Leopoldo Costarelli; Antonella Spila; Francesco Cavaliere; Bruce Huang; Romaine I Fernando; Duane H Hamilton; Caroline Jochems; Kwong-Yok Tsang; Qing Cheng; H Kim Lyerly; Jeffrey Schlom; Fiorella Guadagni Journal: J Natl Cancer Inst Date: 2014-05-09 Impact factor: 13.506
Authors: Ana M Gonzalez-Angulo; Xiudong Lei; Richardo H Alvarez; Majorie C Green; James L Murray; Vicente Valero; Kimberly B Koenig; Nuhad K Ibrahim; Jennifer K Litton; Lakshmy Nair; Savitri Krishnamurthy; Gabriel N Hortobagyi; Funda Meric-Bernstam Journal: Clin Breast Cancer Date: 2015-03-24 Impact factor: 3.225
Authors: Yiing Lin; Shin Lin; Mark Watson; Kathryn M Trinkaus; Sacha Kuo; Michael J Naughton; Katherine Weilbaecher; Timothy P Fleming; Rebecca L Aft Journal: Breast Cancer Res Treat Date: 2009-12-06 Impact factor: 4.872